Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer
A phase 3 trial testing Monalizumab in head and neck squamous cell carcinoma, active and no longer recruiting.
Overview
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer is a phase 3 interventional study registered as NCT04590963, led by AstraZeneca with Innate Pharma, and active but no longer recruiting when checked on 2026-09-11. Official title: A Phase 3 Randomised, Double-blind, Multicenter, Global Study of Monalizumab or Placebo in Combination With Cetuximab in Participants With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With an Immune Checkpoint Inhibitor. Planned enrolment is 370 participants (actual). The study started in 2020-10-02 and primary completion is expected in 2022-05-11. Results have been posted on ClinicalTrials.gov; they are not yet summarised here.
Similar pages
not linked directly; found by shared links- TrialA Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer
Shares Monalizumab, AstraZeneca and the tag ctgov-ingest.
- TrialA Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
Shares AstraZeneca and the tag ctgov-ingest.
- TrialSaruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
Shares AstraZeneca and the tag ctgov-ingest.
- TrialA Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation
Shares AstraZeneca and the tag ctgov-ingest.
- TrialA Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy
Shares AstraZeneca and the tag ctgov-ingest.
- TrialAZD0486 1L Therapy for Elderly or Unfit Participants With LBCL
Shares AstraZeneca and the tag ctgov-ingest.
- TrialAZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer
Shares AstraZeneca and the tag ctgov-ingest.
- TrialA Phase 3 Study of AK112 Plus AK117 Versus Pembrolizumab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Shares Head and neck squamous cell carcinoma and the tag ctgov-ingest.